probucol has been researched along with Cold Fingers, Hereditary in 2 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study cohort included patients with systemic sclerosis (SSc; n = 20), primary Raynaud's phenomenon (n = 15) or 'autoimmune Raynaud's' (n = 5)." | 2.69 | Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. ( Black, CM; Bruckdorfer, KR; Bunce, TD; Denton, CP; Dorado, MB; Howell, K; Roberts, Z; Wilson, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denton, CP | 1 |
| Bunce, TD | 1 |
| Dorado, MB | 1 |
| Roberts, Z | 1 |
| Wilson, H | 1 |
| Howell, K | 1 |
| Bruckdorfer, KR | 1 |
| Black, CM | 1 |
| Simonini, G | 1 |
| Pignone, A | 1 |
| Generini, S | 1 |
| Falcini, F | 1 |
| Cerinic, MM | 1 |
| Gabriele, S | 1 |
| Alberto, P | 1 |
| Sergio, G | 1 |
| Fernanda, F | 1 |
| Marco, MC | 1 |
1 review available for probucol and Cold Fingers, Hereditary
| Article | Year |
|---|---|
Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.
Topics: Antioxidants; Ascorbic Acid; beta Carotene; Endothelium, Vascular; Humans; In Vitro Techniques; Mela | 2000 |
1 trial available for probucol and Cold Fingers, Hereditary
| Article | Year |
|---|---|
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.
Topics: Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Cohort Studies; Humans; Lipoproteins; Lipopro | 1999 |